LEADER 05644nam 2201513z- 450 001 9910557641503321 005 20240122104458.0 035 $a(CKB)5400000000045038 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69333 035 $a(EXLCZ)995400000000045038 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBacteriophages$eAlternatives to Antibiotics and Beyond 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (390 p.) 311 $a3-03943-404-7 311 $a3-03943-405-5 330 $aThere is talk of an upcoming antibiotic armageddon, with untreatable post-operative infections, and similarly untreatable complications after chemotherapy. Indeed, the now famous ?O?Neill Report? (https://amr-review.org/) suggests that, by 2050, more people might die from antibiotic-resistant bacterial infections than from cancer. While we are still learning all the subtle drivers of antibiotic resistance, it seems increasingly clear that we need to take a ?one health? approach, curtailing the use of antibiotics in both human and veterinary medicine. However, there are no new classes of antibiotics on our horizon. Maybe something that has been around ?forever? can come to our rescue?bacteriophages! Nevertheless, it is also necessary to do things differently, and use these new antimicrobials appropriately. Therefore, an in-depth study of bacteriophage biology and case-by-case applications might be required. Whilst by no means comprehensive, this book does cover some of the many topics related to bacteriophages as antimicrobials, including their use in human therapy and aquaculture. It also explores the potential use of phage endolysins as substitutes of antibiotics in two sectors where there is an urgent need?human therapy and the agro-food industry. Last but not least, there is an excellent perspective article on phage therapy implementation. 517 $aBacteriophages 606 $aMedicine$2bicssc 610 $abacteriophages 610 $adairy industry 610 $apathogens 610 $alactic acid bacteria 610 $afermentation failure 610 $abiofilms 610 $aantimicrobial resistance 610 $aantimicrobials 610 $alysins 610 $ahorizontal gene transfer, transduction 610 $abiofilm 610 $aphage therapy 610 $aresistance 610 $abacteriophage 610 $amodels 610 $aagent based 610 $amass action 610 $abacterial phage resistance 610 $aregression modeling 610 $aMRSA 610 $aClostridium difficile 610 $aClostridium difficile infection 610 $amicrobiome 610 $ain vitro fermentation model 610 $amarine vibrios 610 $abiological control 610 $aaquaculture 610 $ainteractions 610 $avibriosis 610 $aAeromonas hydrophila 610 $aMotile Aeromonas Septicemia 610 $aMAS 610 $amultiple-antibiotic-resistance 610 $astriped catfish (Pangasianodon hypophthalmus) 610 $aendolysin 610 $aantibiotics 610 $aone health 610 $aprotein engineering 610 $aAeromonas salmonicida 610 $afurunculosis 610 $aphage-resistant mutants 610 $aproteins 610 $ainfrared spectroscopy 610 $alysin 610 $alytic enzyme 610 $apeptidoglycan hydrolase 610 $aantimicrobial 610 $aantibacterial 610 $aantibiotic resistance 610 $abacteriophage therapy 610 $aNagoya Protocol 610 $aCRISPR CAS 610 $aphage isolation 610 $aphage resistance 610 $aStaphylococcus 610 $aKayvirus 610 $aVibrio anguillarum 610 $afish larvae 610 $achallenge trials 610 $aphage display 610 $aenzybiotics 610 $aBacteriophages 610 $adiabetic foot ulcer 610 $aosteomyelitis 610 $aStaphylococcus aureus 610 $aAntibiotic-resistant bacteria 610 $alysogenic conversion 610 $aprophage induction 610 $aread recruitment 610 $ashiga toxin 610 $aAmerican Foulbrood 610 $aphage 610 $aPaenibacillus larvae 610 $aBrevibacillus laterosporus 610 $atreatment 610 $asafety 610 $abystander phage therapy 610 $aMycobacterium smegmatis 610 $amycobacteriophages 610 $adirected evolution 610 $aPlyC CHAP 610 $aprotein net charge 610 $aCBD-independent 610 $aFoldX 610 $aSTEC-specific bacteriophage 610 $awhole genome sequencing 610 $aSTEC O145 strains 610 $aantimicrobial agent 610 $aPseudomonas aeruginosa 610 $adual-species 610 $aantibiotic 610 $asynergy 610 $asimultaneous 610 $asequential 610 $amicrobiome therapy 610 $aevolution 615 7$aMedicine 700 $aSuárez$b Pilar García$4edt$01305903 702 $aFernández$b Lucía$4edt 702 $aSuárez$b Pilar García$4oth 702 $aFernández$b Lucía$4oth 906 $aBOOK 912 $a9910557641503321 996 $aBacteriophages$93027995 997 $aUNINA